Navigation Links
Keryx Biopharmaceuticals Receives Nasdaq Notification
Date:4/25/2008

ese requirements. Under the rules of the Nasdaq Capital Market, the Company would have an additional 180-calendar day compliance period through April 17, 2009 to comply with the $1.00 minimum closing bid price requirement on the Nasdaq Capital Market, provided the Company otherwise meets the continued listing requirements for the Nasdaq Capital Market.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward- looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
2. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
3. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
4. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
6. Keryx Biopharmaceuticals Announces Additions to Management Team
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
10. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
11. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2015)... ON , April 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... periods ended December 31, 2014. Biorem,s complete fiscal 2014 year-end financial statements ... FINANCIAL HIGHLIGHTS: 2014 , 2013 , 2014 ... 10,683 , 19,596 Gross profit 1,326 , 1,703 ... 1,191 , 1,493 , 3,377 , ...
(Date:4/29/2015)... -- Cambrex Corporation (NYSE: CBM ) announced that first ... 1, 2015 before the market opens. , ... conference call to discuss the financial results. First Quarter 2015 ... Friday, May 1, 2015 at 8:30 a.m. Eastern Time ... International  Passcode:  7993632 Dial-in Replay: , ...
(Date:4/29/2015)... Poway, CA (PRWEB) April 29, 2015 ... proud to announce that its regenerative stem cell therapy ... founded in 2002, seeking to discover a successful treatment ... ligaments. , In 2003 VetStem signed a worldwide exclusive ... veterinary application, and the first horse was treated in ...
(Date:4/29/2015)... , April 29, 2015 /CNW/ - Northern Biologics Inc., ... Ventures, today announced an exclusive, strategic collaboration with ... Biologics received a US$30 million upfront cash payment. ... develop first-in-class therapeutic antibodies, and will have the ... the advancement of its portfolio. ...
Breaking Biology Technology:Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2Northern Biologics and Celgene Enter Strategic Collaboration 2
... Evaluable Patients Had Confirmed Partial Responses (25%); ... Antonio Breast Cancer Symposium, HAYWARD, Calif., Dec. ... today announced that its Hsp90 inhibitor,tanespimycin, demonstrated meaningful ... in patients with HER2-positive metastatic breast cancer,when administered ...
... Global Biotechnology Company Adopts Pharsight,s Groundbreaking ... Automation Software, ... ), a leading provider of software and strategic,services for optimizing clinical ... purchased WinNonlin AutoPilot.,This sale marks Pharsight,s third new customer win since ...
... New Deal Provides a Further Opportunity for OGeS ... Sciences (UK) Ltd "OGeS" announces today that it ... discover, develop and,commercialise novel therapeutic antibodies for the ... to further strengthen its pipeline,of fully human therapeutic ...
Cached Biology Technology:Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer 2Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer 3Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer 4Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer 5Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer 2Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer 3Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 2Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 3
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
(Date:4/9/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the third quarter ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-438-5524 ...
(Date:4/2/2015)... BETHESDA, Md. , April 2, 2015 ... Salt Lake City , the American ... election of five new directors to its Board.  Members ... for the ACMG and for forming and advancing its ... the medical genetics profession. "It,s an eventful ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... meaning and are made with the expectation of specific ... from the University of St. Andrews in the UK. ... significant step forward with the authors, new systematic approach ... non-humans, applied here to a group of orangutan gestures. ...
... burgeon in the atmosphere causing the Earth,s climate to warm, ... gas from the atmosphere and store it where it can ... of Iceland has been studying the possibility of sequestration of ... findings today to several thousand geochemists from around the world ...
... the College of Engineering at the University of Miami ... 25 years to enhancing IEEE,s image and improving the ... being honored with the 2010 IEEE Richard M. Emberson ... technology for humanity. , "I am deeply honored by ...
Cached Biology News:Signal like you mean it 2Storing carbon dioxide deep underground in rock form 2Dean of the UM College of Engineering to receive 2010 IEEE Richard M. Emberson Award 2Dean of the UM College of Engineering to receive 2010 IEEE Richard M. Emberson Award 3
... SYBR Green I nucleic acid gel stain ... that has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... acid stain has also found uses in capillary ...
... acid gel stain has bright fluorescence when bound ... it ideal for detecting dsDNA in gels using ... Green I nucleic gel acid stain has ... assays and bandshift assays. One mL stains 100 ...
... In 1959, McCoy and his ... requirements for in vitro cultivation ... studies were performed using,Basal Medium ... create a new medium known ...
... advanced protein cross-linking techniques are defined by ... Shan S. Wong. This valuable hardcover guide ... and current application references. More than 300 ... cross-linking and conjugate preparation from selection ...
Biology Products: